Results 11 to 20 of about 31,170 (214)
Losartan Inhibits SARS-CoV-2 Replication in Vitro [PDF]
Journal of Pharmacy & Pharmaceutical Sciences, 2021 Purpose: SARS-CoV-2 infection is associated with substantial mortality and high morbidity. This study tested the effect of angiotensin II type I receptor blocker, losartan, on SARS-CoV-2 replication and inhibition of the papain-like protease of the virus.
Reza Nejat +6 more
doaj +2 more sources
Angiotensin II Type 1 Receptor Antagonist Losartan Inhibits TNF-α-Induced Inflammation and Degeneration Processes in Human Nucleus Pulposus Cells [PDF]
Applied Sciences, 2021 Our recent study detected the expression of a tissue renin–angiotensin system (tRAS) in human intervertebral discs (IVDs). The present study sought to investigate the impact of the angiotensin II receptor type 1 (AGTR1) antagonist losartan on human ...
Babak Saravi +12 more
doaj +2 more sources
Arquivos Brasileiros de Cardiologia, 2000 OBJECTIVE: To compare the regression of left ventricular hypertrophy in patients with moderate hypertension treated with enalapril, losartan or a combination of the two drugs at lower doses.
Antônio Carlos Avanza Jr +2 more
doaj +2 more sources
International Journal of Nephrology and Renovascular Disease, 2010 Elizabeth Ripley, Ari HirschDivision of Nephrology, Virginia Commonwealth University, Richmond, Virginia, USAAbstract: Losartan, the first AT1 receptor blocker (ARB), was FDA approved 15 years ago.During those years, researchers and clinicians have ...
Elizabeth Ripley, Ari Hirsch
doaj +1 more source
Expert Approaches to the Assessment of Losartan Drugs Bioequivalence
Регуляторные исследования и экспертиза лекарственных средств, 2020 Angiotensin II receptor antagonists (ARAs) are one of the most promising classes of antihypertensive drugs. They are most widely represented on the Russian market by losartan drugs which total 24 items.
D. P. Romodanovsky, D. V. Goryachev
doaj +3 more sources
Cardiology and TherapyIntroduction Cardiovascular diseases are a leading cause of global mortality, with hypertension as a major risk factor. Low control rates are often attributed to monotherapy, while evidence and clinical guidelines support the effectiveness of combination
Isabel E. Rucker-Joerg +8 more
doaj +2 more sources
ChemInform, 2004 The title compound (systematic name: [2-butyl-4-chloro-1-[2'-(2-trityl-2H-tetrazol-5-yl)biphenyl-4-ylmethyl]-1H-imidazol-5-yl]methanol), C(41)H(37)ClN(6)O, crystallizes in the centrosymmetric space group P-1 with two independent molecules in the asymmetric unit.
Sieron, L. +6 more
openaire +2 more sources
Orthopaedic Journal of Sports Medicine, 2021 Objectives: 1. To determine the dosage and beneficial effects of intra-articular injection of losartan on microfracture-mediated cartilage repair and normal cartilage homeostasis.
Xueqin Gao +10 more
doaj +1 more source
Effectiveness of Losartan-Loaded Hyaluronic Acid (HA) Micelles for the Reduction of Advanced Hepatic Fibrosis in C3H/HeN Mice Model. [PDF]
PLoS ONE, 2015 Advanced hepatic fibrosis therapy using drug-delivering nanoparticles is a relatively unexplored area. Angiotensin type 1 (AT1) receptor blockers such as losartan can be delivered to hepatic stellate cells (HSC), blocking their activation and thereby ...
Reju George Thomas +4 more
doaj +1 more source
Pilot study of losartan for pulmonary hypertension in chronic obstructive pulmonary disease. [PDF]
, 2005 BACKGROUND: Morbidity in COPD results from a combination of factors including hypoxia-induced pulmonary hypertension, in part due to pulmonary vascular remodelling. Animal studies suggest a role of angiotensin II and acute studies in man concur.
Shakur, B Haleema +17 more
core +1 more source